It usually starts with something that doesn’t make sense. Your feet feel numb in a way that isn’t quite numb. Your hands fumble buttons. You trip going up a curb you’ve stepped over a thousand times. By the time someone says the word CIDP — chronic inflammatory demyelinating polyneuropathy — you’ve been to three doctors and had two MRIs and an electrodiagnostic test, and you’re tired.
If your story sounds like that, or if it sounds more like the rapid weakness of Guillain-Barré syndrome, or the asymmetric weakness of multifocal motor neuropathy (MMN), you’re in the right article. These are autoimmune diseases that attack the peripheral nerves — the nerves outside the brain and spinal cord — and for many patients, IVIG is the treatment that brings them back.
This guide explains what these conditions are, how IVIG works to treat them, what the dosing and response timeline actually looks like, what to expect from maintenance therapy, and where home infusion fits in. We’ll be honest about the parts that take patience: response can be slow at first, dosing isn’t one-size-fits-all, and maintenance is often lifelong. But the headline is hopeful. For most CIDP patients, IVIG works.
| Starting IVIG for CIDP, GBS, or MMN? Our pharmacists specialize in immunoglobulin therapy for neurological conditions. We coordinate every infusion, monitor your response, and handle the insurance side. ▶ Call (949) 555-0100 · Talk to Our Neuro-IVIG Team |
The Conditions: What’s Happening, in Plain English
All three conditions covered in this article are autoimmune attacks on the peripheral nervous system — the nerves that control movement, sensation, and reflexes outside the brain and spinal cord. They differ in how they start, how fast they progress, and which nerves they target.
CIDP — Chronic Inflammatory Demyelinating Polyneuropathy
The most common chronic autoimmune neuropathy. Your immune system attacks the myelin sheath that insulates peripheral nerves, slowing nerve conduction and causing weakness, numbness, tingling, and loss of reflexes. CIDP develops gradually over 8 weeks or longer. Without treatment, it progresses or relapses repeatedly. With treatment, many patients regain significant function.
Guillain-Barré Syndrome (GBS)
The acute cousin of CIDP. GBS causes similar nerve damage but develops rapidly, often over days to a few weeks, sometimes following an infection. It can progress to severe weakness or even paralysis requiring ICU care. With treatment (IVIG or plasmapheresis) and time, most GBS patients recover substantially, though recovery can take months and some residual weakness is common.
Multifocal Motor Neuropathy (MMN)
A less common autoimmune neuropathy that targets motor nerves asymmetrically — typically affecting one limb more than another. Patients often notice weakness in specific muscles (a hand grip that’s lost strength, a foot that drags) without the sensory symptoms of CIDP. MMN progresses slowly and responds well to IVIG, though it generally doesn’t respond to corticosteroids the way CIDP does.
| Feature | CIDP | Guillain-Barré (GBS) | MMN |
|---|---|---|---|
| Onset | Gradual (8+ weeks) | Rapid (days to 4 weeks) | Gradual (months) |
| Symptoms | Symmetric weakness, numbness, tingling | Rapid symmetric weakness, paralysis | Asymmetric muscle weakness |
| Course | Chronic / relapsing | Acute, mostly self-limited | Chronic / progressive |
| First-line treatment | IVIG, steroids, or plasmapheresis | IVIG or plasmapheresis | IVIG (steroids ineffective) |
| Long-term IVIG | Often required | Usually not | Usually required |
How IVIG Helps in Autoimmune Neuropathy
IVIG (intravenous immunoglobulin) is a concentrated solution of antibodies pooled from thousands of healthy donors. In autoimmune neuropathies, IVIG works through several mechanisms simultaneously:
- It dilutes and neutralizes the autoantibodies that are attacking your nerves
- It modulates immune cell activity, reducing the inflammatory attack on myelin
- It saturates Fc receptors on immune cells, blocking destructive signaling
- It accelerates clearance of pathogenic antibodies from your circulation
- It promotes regulatory T-cell activity, helping reset immune balance
The exact mechanism varies by condition, but the practical result is similar: the immune attack quiets down, nerve function recovers as remyelination occurs, and patients often regain meaningful strength and sensation. For CIDP and MMN, the effect typically requires repeat treatments to maintain. For GBS, a single course is often sufficient because the disease is self-limited.
| 💡 IVIG is not a cure — it’s an ongoing immune reset In CIDP and MMN, IVIG suppresses the autoimmune attack but doesn’t permanently fix what triggered it. That’s why most patients need maintenance infusions every 2 to 8 weeks (often every 3-4 weeks) for years. The good news: the maintenance is what keeps you functional, not what treats you back from a flare. |
What the IVIG Timeline Actually Looks Like
The loading dose
Most patients start with a loading dose — a high total dose split across 2 to 5 days. The standard regimen is 2 g/kg of body weight, divided. For a 75 kg (165 lb) adult, that’s 150 grams of IVIG total, typically given as 30-50 grams over each of 3-5 consecutive days.
Loading doses are demanding. Each infusion takes 4 to 6 hours, sometimes longer for the first dose, and infusion centers space them across consecutive days or every other day. Side effects (headache, fatigue, body aches) are most common during this initial loading phase as your body adjusts to the high antibody load.
Response time
In GBS, IVIG response typically begins within 1 to 2 weeks of the loading dose, with continued recovery over weeks to months as nerves repair.
In CIDP, response varies. Some patients notice improvement within days to a couple of weeks. Others take 4 to 8 weeks to see meaningful change. A small percentage — about 20-30% of CIDP patients — don’t respond well to IVIG and may need plasmapheresis, steroids, or other treatments instead.
In MMN, response usually emerges over 2 to 6 weeks, with improvement in muscle strength and sometimes reduction of fasciculations.
Maintenance therapy
After loading, CIDP and MMN patients move to a maintenance schedule: typically 1 g/kg every 3 to 4 weeks, sometimes adjusted up to every 2 weeks or down to every 6-8 weeks based on response. The dose and frequency are calibrated to keep you stable without overtreating.
Maintenance infusions are shorter (3 to 4 hours) than loading doses and are often well-tolerated once your body has acclimated. Many CIDP patients describe this as a manageable rhythm: one day every few weeks, then back to normal life.
| ⚠️ If your symptoms worsen as the next infusion approaches This pattern — feeling great after an infusion, gradually declining as you near your next dose — is called the ‘wearing off’ effect, and it’s common in CIDP. It signals that your dosing interval may need to shorten or your dose may need to increase. Tell your neurologist. The schedule can be adjusted, and most patients find a sweet spot where symptoms stay quiet between doses. |
Home IVIG and the SCIG Alternative
After a few stable months of IVIG at an infusion center, many CIDP and MMN patients ask the same question: can I do this at home? The answer is usually yes — and increasingly, the answer is also have you considered SCIG?
Home IVIG
With insurance approval, IVIG can be administered at home with a trained infusion nurse. Setup is similar to a center: IV access, premedication, slow infusion over 4-6 hours, monitoring throughout. Many patients prefer the comfort of home, especially after years of infusion-center visits. Home IVIG is widely covered by commercial insurance and Medicare for stable CIDP and MMN patients.
SCIG (subcutaneous immunoglobulin)
SCIG delivers the same medication class through a small needle under the skin, in a much smaller weekly dose. Patients self-administer at home using a small pump, typically once a week. The benefits for CIDP patients in particular:
- Steady-state antibody levels (no peaks and valleys, no wearing-off effect)
- Far fewer systemic side effects (no infusion-day headaches or fatigue)
- No more IV access or center visits
- Greater scheduling flexibility for travel and life
Hizentra is FDA-approved specifically for CIDP at maintenance doses, and increasingly used after the loading phase. Not every CIDP patient is a SCIG candidate — patients with very high dose requirements may not be practical on SCIG, and acute or recently-flaring patients usually need IVIG’s faster onset. But for stable maintenance, SCIG is a real option that more neurologists are recommending. We have a companion guide on SCIG vs IVIG that walks through the decision in detail.
| Considering home IVIG or switching to SCIG? Our pharmacists work with your neurologist to evaluate the switch, run benefits, and coordinate training. Many of our CIDP patients have been on home or SCIG therapy for years. ▶ Schedule a Consult · (949) 555-0100 |
Side Effects and What to Watch For
Common IVIG side effects
- Headaches — sometimes severe, especially during loading doses. Hydration, slow infusion rates, and premedication help. Aseptic meningitis is a rare but more serious version that requires medical attention.
- Fatigue and body aches — often called the “IVIG hangover.” Most pronounced after loading doses and tends to ease over the 24-48 hours after infusion.
- Fever and chills — more common with new brands or brand changes. Premedication usually controls this.
- Hypertension and fluid considerations — particularly important in older patients or those with cardiac or kidney issues. Slower infusion rates and careful monitoring address most concerns.
- Thrombosis risk — IVIG raises the risk of blood clots in patients with other risk factors. Hydration before and during infusion, and slower infusion rates for high-risk patients, mitigate this.
When to call your team
- Severe headache that doesn’t respond to typical pain relief
- Sudden vision changes, neck stiffness, or confusion (possible aseptic meningitis)
- Chest pain, shortness of breath, or leg swelling (possible clot)
- Fever above 101°F after an infusion
- Allergic-type symptoms (hives, throat swelling, difficulty breathing)
- Sudden return or worsening of neurological symptoms during a stable maintenance period
What If IVIG Isn’t Working?
Roughly 20-30% of CIDP patients don’t respond to IVIG, or stop responding after a period of effectiveness. If your strength isn’t improving, your reflexes haven’t returned, or your nerve conduction studies haven’t changed, your neurologist will consider:
- Plasmapheresis (plasma exchange) — a different way to remove the autoimmune antibodies, also effective for CIDP and GBS
- Corticosteroids — often effective for CIDP (though not MMN), commonly used alongside or instead of IVIG
- Immunosuppressants — azathioprine, mycophenolate, methotrexate, or cyclosporine for refractory cases
- Rituximab — B-cell depletion therapy used for IVIG-refractory CIDP and MMN, especially in cases with anti-MAG or anti-CNTN1 antibodies
- Reconfirming the diagnosis — if treatments aren’t working, sometimes the diagnosis itself needs another look. Conditions that mimic CIDP exist and may respond to different therapies.
This isn’t a failure on your part. Treatment-refractory neuropathy is real, and your neurologist has options. The conversation about “what’s next” is a normal part of CIDP and MMN management for a meaningful subset of patients.
How a Specialty Pharmacy Supports Neuro-IVIG Patients
IVIG for autoimmune neuropathy is a long-term partnership. Many of our CIDP and MMN patients have been with us for 5, 10, or 15+ years. What we coordinate:
- Reliable IVIG product delivery on your dosing schedule, with consistency of brand whenever possible (changing brands can affect tolerability)
- Coordination with your infusion center, home infusion nurse, or SCIG training team
- Prior authorization and renewal management — IVIG PAs often need to be redone every 6 to 12 months and require detailed clinical documentation
- Co-pay assistance through manufacturer programs (many IVIG brands have $0 co-pay programs for commercial patients) and foundation grants for Medicare patients
- Clinical pharmacist availability for side effect questions, premedication adjustments, and dose timing
- Brand-stability advocacy — keeping you on the same product when possible to minimize tolerability issues from brand switches
- Coordination with your neurologist on maintenance dose adjustments
IVIG can be a logistical nightmare without a dedicated specialty pharmacy. With one, it becomes a quiet, predictable part of your life — medication arrives, infusions happen, and you focus on living. That’s the goal.
| Want a specialty pharmacy that knows neuro-IVIG? Whether you’re starting IVIG, switching brands, considering SCIG, or just want better support on maintenance — talk to our team. ▶ Contact River’s Edge · (949) 555-0100 |
Frequently Asked Questions
Q: How quickly will I notice improvement on IVIG?
It varies by condition. GBS patients often start improving within 1-2 weeks. CIDP response can be days to 8 weeks; some patients respond dramatically and quickly, others gradually. MMN typically takes 2-6 weeks. If you don’t notice change after a full loading course (about 6-8 weeks), your neurologist will reassess.
Q: How long will I need to be on IVIG?
GBS is usually a one-course treatment, sometimes repeated if symptoms recur. CIDP and MMN typically require ongoing maintenance therapy for years, often for life. Some CIDP patients eventually wean off IVIG into stable remission, but this is the exception rather than the rule.
Q: Can I do CIDP treatment at home?
Yes. After your initial loading dose at an infusion center, most CIDP patients can transition to home IVIG with a visiting nurse. An increasing number of stable maintenance patients are also switching to SCIG (Hizentra), which is self-administered weekly at home. Both are widely covered by insurance for CIDP.
Q: What’s the difference between IVIG for CIDP and IVIG for primary immunodeficiency?
It’s the same medication class, but the dose and frequency differ. Primary immunodeficiency patients receive lower doses (typically 0.4-0.6 g/kg per month) to maintain protective antibody levels. CIDP and MMN patients receive higher maintenance doses (typically around 1 g/kg every 3-4 weeks) to suppress the autoimmune attack on nerves.
Q: Will my insurance cover IVIG for CIDP?
Yes, virtually all commercial insurance, Medicare, and Medicaid plans cover IVIG for CIDP, GBS, and MMN. CIDP and MMN coverage typically requires documented diagnosis with electrodiagnostic confirmation and ongoing prescriber justification at PA renewal. Your specialty pharmacy will handle the documentation.
Q: Are there alternatives if IVIG isn’t working for me?
Yes. For CIDP, plasmapheresis, corticosteroids, immunosuppressants, and rituximab are all options. For MMN, IVIG is the most reliably effective first-line treatment, but rituximab and cyclophosphamide are alternatives for refractory cases. Your neurologist will discuss the right next step if IVIG isn’t producing the response you need.
| 💡 Schema markup note for developers FAQPage schema for the 6 Q&As. MedicalCondition schema for chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome, and multifocal motor neuropathy with appropriate ICD-10 codes. Drug schema entries for major IVIG brands (Privigen, Gammagard, Octagam, Gamunex) and Hizentra for SCIG. Author Person schema with credential PharmD. |
The Takeaway
CIDP, GBS, and MMN are different diseases with overlapping treatment paths, and IVIG is the cornerstone of how most patients manage them. The journey isn’t always linear — loading doses are demanding, response timelines vary, and finding the right maintenance schedule takes some calibration. But for most patients, IVIG works. Strength returns. Function comes back. The disease quiets down.
What makes that journey sustainable is the team. A neurologist who knows neuro-IVIG dosing, an infusion partner you trust, and a specialty pharmacy that handles the medication logistics, the brand consistency, the prior authorization renewals, and the side effect questions. With those pieces in place, the medical part of your condition takes up less of your life. That’s the goal we’re working toward, every infusion.